bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Video S1 from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
Authors: Xiao Lin , Somers Klaartje , Murray Jayne , Pandher Ruby , Karsa Mawar , Ronca Emma , Bongers Angelika , Terry Rachael , Ehteda Anahid , Gamble Laura D. , Issaeva Natalia , Leonova Katerina I. , O'Connor Aisling , Mayoh Chelsea , Venkat Pooja , Quek Hazel , Brand Jennifer , Kusuma Frances K. , Pettitt Jessica A. , Mosmann Erin , Kearns Adam , Eden Georgina , Alfred Stephanie , Allan Sophie , Zhai Lei , Kamili Alvin , Gifford Andrew J. , Carter Daniel R. , Henderson Michelle J. , Fletcher Jamie I. , Marshall Glenn , Johnstone Ricky W. , Cesare Anthony J. , Ziegler David S. , Gudkov Andrei V. , Gurova Katerina V. , Norris Murray D. , Haber Michelle
Published: April 2023

HT10806TG_Control
Supplementary Table 3 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Authors: de Bono Johann S. , Fleming Mark T. , Wang Judy S. , Cathomas Richard , Miralles Manuel Selvi , Bothos John , Hinrichs Mary Jane , Zhang Qu , He Peng , Williams Marna , Rosenbaum Anton I. , Liang Meina , Vashisht Kapil , Cho Song , Martinez Pablo , Petrylak Daniel P.
Published: April 2023

ADA responses
Supplementary Figures from Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
Authors: Xiao Lin , Somers Klaartje , Murray Jayne , Pandher Ruby , Karsa Mawar , Ronca Emma , Bongers Angelika , Terry Rachael , Ehteda Anahid , Gamble Laura D. , Issaeva Natalia , Leonova Katerina I. , O'Connor Aisling , Mayoh Chelsea , Venkat Pooja , Quek Hazel , Brand Jennifer , Kusuma Frances K. , Pettitt Jessica A. , Mosmann Erin , Kearns Adam , Eden Georgina , Alfred Stephanie , Allan Sophie , Zhai Lei , Kamili Alvin , Gifford Andrew J. , Carter Daniel R. , Henderson Michelle J. , Fletcher Jamie I. , Marshall Glenn , Johnstone Ricky W. , Cesare Anthony J. , Ziegler David S. , Gudkov Andrei V. , Gurova Katerina V. , Norris Murray D. , Haber Michelle
Published: April 2023

Supplementary Figures S1-S16
Supplementary Figure 2 from Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide
Authors: de Bono Johann S. , Fleming Mark T. , Wang Judy S. , Cathomas Richard , Miralles Manuel Selvi , Bothos John , Hinrichs Mary Jane , Zhang Qu , He Peng , Williams Marna , Rosenbaum Anton I. , Liang Meina , Vashisht Kapil , Cho Song , Martinez Pablo , Petrylak Daniel P.
Published: April 2023

Mutation profiles in ctDNA: truncating and/or pathogenic mutations in DDR or DDR-related pathway
Supplementary Data from Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy
Authors: Clauser Paola , Krug Barbara , Bickel Hubert , Dietzel Matthias , Pinker Katja , Neuhaus Victor-Frederic , Marino Maria Adele , Moschetta Marco , Troiano Nicoletta , Helbich Thomas H. , Baltzer Pascal A.T.
Published: April 2023

Supplemental Material 1-5
Figure S2 from Quantification of Translocation-Specific ctDNA Provides an Integrating Parameter for Early Assessment of Treatment Response and Risk Stratification in Ewing Sarcoma
Authors: Krumbholz Manuela , Eiblwieser Johanna , Ranft Andreas , Zierk Jakob , Schmidkonz Christian , Stütz Adrian M , Peneder Peter , Tomazou Eleni M. , Agaimy Abbas , Bäuerle Tobias , Hartmann Wolfgang , Dirksen Uta , Metzler Markus
Published: April 2023

Event-free survival (EFS) and overall survival (OS) by sex, age at diagnosis, pelvis localization, tumor volume, presence of metastases, and histological response in patients with EWS.
Table S5 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S5
Table S1 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Table S1
Supplementary Legend from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Supplementary Legend
Figure S3 from Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies
Authors: Tayari Mina M. , Santos Helena G. Dos , Kwon Deukwoo , Bradley Terrence J. , Thomassen Amber , Chen Charles , Dinh Yvonne , Perez Aymee , Zelent Arthur , Morey Lluis , Cimmino Luisa , Shiekhattar Ramin , Swords Ronan T. , Watts Justin M.
Published: April 2023

Supplementary Figure S3. Effect of ATRA-TCP treatment on AML cell lines.
Supplementary Table from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Authors: Ferrarotto Renata , Amit Moran , Nagarajan Priyadharsini , Rubin M. Laura , Yuan Ying , Bell Diana , El-Naggar Adel K. , Johnson Jason M. , Morrison William H. , Rosenthal David I. , Glisson Bonnie S. , Johnson Faye M. , Lu Charles , Mott Frank E. , Esmaeli Bita , Diaz Eduardo M. , Gidley Paul W. , Goepfert Ryan P. , Lewis Carol M. , Weber Randal S. , Wargo Jennifer A. , Basu Sreyashi , Duan Fei , Yadav Shalini S. , Sharma Padmanee , Allison James P. , Myers Jeffrey N. , Gross Neil D.
Published: April 2023

Supplementary Table from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Supplementary Figure from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Authors: Ferrarotto Renata , Amit Moran , Nagarajan Priyadharsini , Rubin M. Laura , Yuan Ying , Bell Diana , El-Naggar Adel K. , Johnson Jason M. , Morrison William H. , Rosenthal David I. , Glisson Bonnie S. , Johnson Faye M. , Lu Charles , Mott Frank E. , Esmaeli Bita , Diaz Eduardo M. , Gidley Paul W. , Goepfert Ryan P. , Lewis Carol M. , Weber Randal S. , Wargo Jennifer A. , Basu Sreyashi , Duan Fei , Yadav Shalini S. , Sharma Padmanee , Allison James P. , Myers Jeffrey N. , Gross Neil D.
Published: April 2023

Supplementary Figure from Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Supplementary Data from CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
Authors: Labiano Sara , Roh Vincent , Godfroid Céline , Hiou-Feige Agnès , Romero Jackeline , Sum Eva , Rapp Moritz , Boivin Gael , Wyss Tania , Simon Christian , Bourhis Jean , Umaña Pablo , Trumpfheller Christine , Tolstonog Genrich V. , Vozenin Marie-Catherine , Romero Pedro
Published: April 2023

7 SUPPLEMENTARY FIGURES INCLUDING THE LEGENDS
Supplementary from Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors
Authors: Koutros Stella , Rao Nina , Moore Lee E. , Nickerson Michael L. , Lee Donghyuk , Zhu Bin , Pardo Larissa A. , Baris Dalsu , Schwenn Molly , Johnson Alison , Jones Kristine , Garcia-Closas Montserrat , Prokunina-Olsson Ludmila , Silverman Debra T. , Rothman Nathaniel , Dean Michael
Published: April 2023

Supplementary
Supplementary Data from Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling
Authors: Oh Juhyun , Carlson Jonathan C.T. , Landeros Christian , Lee Hakho , Ferguson Scott , Faquin William C. , Clark John R. , Pittet Mikael J. , Pai Sara I. , Weissleder Ralph
Published: April 2023

All supplementary data included
Supplementary Figure 8 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 8. Proposed mechanisms and clinical application for the ACTIV+Pano treatment.
Supplementary Figure 1 from A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer
Authors: Ali Aesha I. , Wang Minyu , von Scheidt Bianca , Dominguez Pilar M. , Harrison Aaron J. , Tantalo Daniela G.M. , Kang Jian , Oliver Amanda J. , Chan Jack D. , Du Xin , Bai Yuchen , Lee Belinda , Johnstone Ricky W. , Darcy Phillip K. , Kershaw Michael H. , Slaney Clare Y.
Published: April 2023

Supplementary Figure 1. Panc02-Her2, KPC-Her2 and 24JK-Her2 cells express comparable levels of Her2.
Figure S4 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Authors: Chakraborty Goutam , Patail Nabeela Khan , Hirani Rahim , Nandakumar Subhiksha , Mazzu Ying Z. , Yoshikawa Yuki , Atiq Mohammad , Jehane Lina E. , Stopsack Konrad H. , Lee Gwo-Shu Mary , Abida Wassim , Morris Michael J. , Mucci Lorelei A. , Danila Daniel , Kantoff Philip W.
Published: April 2023

Figure S4
Figure 6 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

In vivo safety of AZD5991
Figure S1 from Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Authors: Chakraborty Goutam , Patail Nabeela Khan , Hirani Rahim , Nandakumar Subhiksha , Mazzu Ying Z. , Yoshikawa Yuki , Atiq Mohammad , Jehane Lina E. , Stopsack Konrad H. , Lee Gwo-Shu Mary , Abida Wassim , Morris Michael J. , Mucci Lorelei A. , Danila Daniel , Kantoff Philip W.
Published: April 2023

Figure S1
Figure 4 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

ROS scavengers do not abrogate AZD5991-induced apoptosis
Figure 3 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

ROS production in MCL cells
Figure 2 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

Caspase blockade does not abrogate mitochondrial effects of AZD5991
Figure 1 from Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner
Authors: Liu Tingting , Lam Vi , Thieme Elana , Sun Duanchen , Wang Xiaoguang , Xu Fei , Wang Lili , Danilova Olga V. , Xia Zheng , Tyner Jeffrey W. , Kurtz Stephen E. , Danilov Alexey V.
Published: April 2023

Effect of AZD5991 on Bcl-2 family members
Supp FIgure 6 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure
Table S1 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

ctDNA assay and bTMB algorithm methods
Figure S5 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

Comparison of tTMB values
Supp FIgure 2 from Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care
Authors: Chakraborty Saptarshi , Ecker Brett L. , Seier Ken , Aveson Victoria G. , Balachandran Vinod P. , Drebin Jeffrey A. , D'Angelica Michael I. , Kingham T. Peter , Sigel Carlie S. , Soares Kevin C. , Vakiani Efsevia , Wei Alice C. , Chandwani Rohit , Gonen Mithat , Shen Ronglai , Jarnagin William R.
Published: April 2023

Supp FIgure 2
Figure S1 from A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study
Authors: Si Han , Kuziora Michael , Quinn Katie J. , Helman Elena , Ye Jiabu , Liu Feng , Scheuring Urban , Peters Solange , Rizvi Naiyer A. , Brohawn Philip Z. , Ranade Koustubh , Higgs Brandon W. , Banks Kimberly C. , Chand Vikram K. , Raja Rajiv
Published: April 2023

MYSTIC study design
Supplementary Table S1 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Table S1
Supplementary Data from Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma
Authors: Chastkofsky Michael I. , Pituch Katarzyna C. , Katagi Hiroaki , Zannikou Markella , Ilut Liliana , Xiao Ting , Han Yu , Sonabend Adam M. , Curiel David T. , Bonner Erin R. , Nazarian Javad , Horbinski Craig M. , James C. David , Saratsis Amanda M. , Hashizume Rintaro , Lesniak Maciej S. , Balyasnikova Irina V.
Published: April 2023

Methods, Figures, legends and Tables
Supplementary Figures from Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis
Authors: Wu Alex Man Lai , Gossa Selamawit , Samala Ramakrishna , Chung Monika A. , Gril Brunilde , Yang Howard H. , Thorsheim Helen R. , Tran Andy D. , Wei Debbie , Taner Esra , Isanogle Kristine , Yang Yuan , Dolan Emma L. , Robinson Christina , Difilippantonio Simone , Lee Maxwell P. , Khan Imran , Smith Quentin R. , McGavern Dorian B. , Wakefield Lalage M. , Steeg Patricia S.
Published: April 2023

Supplementary Figures
Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Authors: Singh Harshabad , Li Yvonne Y. , Spurr Liam F. , Shinagare Atul B. , Abhyankar Ritika , Reilly Emma , Brais Lauren K. , Nag Anwesha , Ducar Matthew D. , Thorner Aaron R. , Shapiro Geoffrey I. , Keller Rachel B. , Siletti Cheta , Clark Jeffrey W. , Farago Anna F. , Lin Jessica J. , Demetri George D. , Gujrathi Rahul , Kulke Matthew H. , MacConaill Laura E. , Ligon Azra H. , Sicinska Ewa , Meyerson Matthew L. , Meyerhardt Jeffrey A. , Cherniack Andrew D. , Wolpin Brian M. , Ng Kimmie , Giannakis Marios , Hornick Jason L. , Cleary James M.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S2 from Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Authors: Kerbauy Lucila N. , Marin Nancy D. , Kaplan Mecit , Banerjee Pinaki P. , Berrien-Elliott Melissa M. , Becker-Hapak Michelle , Basar Rafet , Foster Mark , Garcia Melo Luciana , Neal Carly C. , McClain Ethan , Daher May , Nunez Cortes Ana Karen , Desai Sweta , Inng Lim Francesca Wei , Mendt Mayela Carolina , Schappe Timothy , Li Li , Shaim Hila , Shanley Mayra , Ensley Emily L. , Uprety Nadima , Wong Pamela , Liu Enli , Ang Sonny O. , Cai Rong , Nandivada Vandana , Mohanty Vakul , Miao Qi , Shen Yifei , Baran Natalia , Fowlkes Natalie W. , Chen Ken , Muniz-Feliciano Luis , Champlin Richard E. , Nieto Yago L. , Koch Joachim , Treder Martin , Fischer Wolfgang , Okamoto Oswaldo Keith , Shpall Elizabeth J. , Fehniger Todd A. , Rezvani Katayoun
Published: April 2023

Supplementary Fig. S2. CD16 expression and IFN-ï�§ production of blood mature and immature NK cells.
Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Authors: Singh Harshabad , Li Yvonne Y. , Spurr Liam F. , Shinagare Atul B. , Abhyankar Ritika , Reilly Emma , Brais Lauren K. , Nag Anwesha , Ducar Matthew D. , Thorner Aaron R. , Shapiro Geoffrey I. , Keller Rachel B. , Siletti Cheta , Clark Jeffrey W. , Farago Anna F. , Lin Jessica J. , Demetri George D. , Gujrathi Rahul , Kulke Matthew H. , MacConaill Laura E. , Ligon Azra H. , Sicinska Ewa , Meyerson Matthew L. , Meyerhardt Jeffrey A. , Cherniack Andrew D. , Wolpin Brian M. , Ng Kimmie , Giannakis Marios , Hornick Jason L. , Cleary James M.
Published: April 2023

Supplementary Tables
Supplementary Figures S1-S7 from STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition
Authors: Sitthideatphaiboon Piyada , Galan-Cobo Ana , Negrao Marcelo V. , Qu Xiao , Poteete Alissa , Zhang Fahao , Liu Diane D. , Lewis Whitney E. , Kemp Haley N. , Lewis Jeff , Rinsurongkawong Waree , Giri Uma , Lee J. Jack , Zhang Jianjun , Roth Jack A. , Swisher Stephen , Heymach John V.
Published: April 2023

Supplementary figures
Supplementary Data from Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
Authors: Taieb Julien , Taly Valérie , Henriques Julie , Bourreau Camille , Mineur Laurent , Bennouna Jaafar , Desrame Jérôme , Louvet Christophe , Lepere Céline , Mabro May , Egreteau Joëlle , Bouche Olivier , Mulot Claire , Hormigos Katia , Chaba Kariman , Mazard Thibault , de Gramont Aimery , Vernerey Dewi , André Thierry , Laurent-Puig Pierre
Published: April 2023

Supplementary Data
Table S1 from Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Authors: Altoe Mirella L. , Kalinsky Kevin , Marone Alessandro , Kim Hyun K. , Guo Hua , Hibshoosh Hanina , Tejada Mariella , Crew Katherine D. , Accordino Melissa K. , Trivedi Meghna S. , Hershman Dawn L. , Hielscher Andreas H.
Published: April 2023

Clinical and pathological characteristics of all the 105 patients enrolled in the clinical study. Patients highlighted (n=17) were excluded from statistical analysis due to the main reasons: patient withdrew from the study (n=4) (blue color); baseline DOTBIS measurement not collected due to instrumentation failure (n=8) (grey color); patient under investigational and not FDA approved drug regimen (n=1) (green color); and machine operator error (n=4) (yellow color).
Supplementary Table S2 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

NECTIN4 guide RNA and qPCR primer sequences used for CRISPRi knockdown and qPCR experiments, respectively.
Supplementary Figure S8 from Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin
Authors: Chu Carissa E. , Sjöström Martin , Egusa Emily A. , Gibb Ewan A. , Badura Michelle L. , Zhu Jun , Koshkin Vadim S. , Stohr Bradley A. , Meng Maxwell V. , Pruthi Raj S. , Friedlander Terence W. , Lotan Yair , Black Peter C. , Porten Sima P. , Feng Felix Y. , Chou Jonathan
Published: April 2023

(A) Validation of knockdown by cell surface staining of NECTIN4 protein expression in HT-1376 cells using CRISPRi/dCas9 and five unique sgRNAs targeting different regions of NECTIN4 gene and promoter. The sgNECTIN4-a guide was used for subsequent experiments. (B) Confirmation of sgNECTIN4 CRISPRi/dCas9-mediated NECTIN4 mRNA knockdown in HT-1376 cells by quantitative PCR, **p<0.01. All sgRNAs decreased NECTIN4 mRNA expression by >90%. (C) Phase-contrast, brightfield microscopy of HT-1376 cells in Control and NECTIN4 knockdown cells to show the morphology of cells. Scale bar = 400 mm. (D) Validation of knockdown by cell surface staining of NECTIN4 protein expression in HT-1197 cells using CRISPRi/dCas9. (E) EV dose-response WST proliferation assay in HT-1197 Control (black) and NECTIN4 (KD) knockdown (purple) cells.
Supplementary figure legend 2 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Authors: Najjar Yana G. , McCurry Dustin , Lin Huang , Lin Yan , Zang Yan , Davar Diwakar , Karunamurthy Arivarasan , Drabick Joseph J. , Neves Rogerio I. , Butterfield Lisa H. , Ernstoff Marc S. , Puzanov Igor , Skitzki Joseph J. , Bordeaux Jennifer , Summit IlaSri B. , Bender Jehovana O. , Kim Ju Young , Chen Beiru , Sarikonda Ghanashyam , Pahuja Anil , Tsau Jennifer , Alfonso Zeni , Laing Christian , Pingpank James F. , Holtzman Matthew P. , Sander Cindy , Rose Amy , Zarour Hassane M. , Kirkwood John M. , Tarhini Ahmad A.
Published: April 2023

Treatment significantly affects the circulating immune compartment.
Supplementary Figure S1 from Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma
Authors: Najjar Yana G. , McCurry Dustin , Lin Huang , Lin Yan , Zang Yan , Davar Diwakar , Karunamurthy Arivarasan , Drabick Joseph J. , Neves Rogerio I. , Butterfield Lisa H. , Ernstoff Marc S. , Puzanov Igor , Skitzki Joseph J. , Bordeaux Jennifer , Summit IlaSri B. , Bender Jehovana O. , Kim Ju Young , Chen Beiru , Sarikonda Ghanashyam , Pahuja Anil , Tsau Jennifer , Alfonso Zeni , Laing Christian , Pingpank James F. , Holtzman Matthew P. , Sander Cindy , Rose Amy , Zarour Hassane M. , Kirkwood John M. , Tarhini Ahmad A.
Published: April 2023

Representative gating strategy illustrating (A) CD4 and CD8 T cell identification (B) expression of ICOS on CD4 positive T cells (C) expression of PD-1 and Ki-67 within PD-1 positive cells and (D) expression of CD38/HLA-DR, PD-1 and KI-67 within CD8+ PD-1+ T cells is shown.
Table S1 from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

Supplementary Table 1. Biodistribution data of [124I]PN67 versus time/h, administrated by i.v. tail-vein injection in BALB/c mice bearing 4T1-Luc tumors. Data is represented as average %ID/g {plus minus} SD with n=5 animals/group.
NMR and HRMS from Imaging of Cancer γ-Secretase Activity Using an Inhibitor-Based PET Probe
Authors: Nie Pengju , Kalidindi Teja , Nagle Veronica L. , Wu Xianzhong , Li Thomas , Liao George P. , Frost Georgia , Henry Kelly E. , Punzalan Blesida , Carter Lukas M. , Lewis Jason S. , Pillarsetty Naga Vara Kishore , Li Yue-Ming
Published: April 2023

NMR and Mass (HRMS) spectroscopy data
Table S2 from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
Authors: Tong Kit I. , Yoon Sharon , Isaev Keren , Bakhtiari Mehran , Lackraj Tracy , He Michael Y. , Joynt Jesse , Silva Anjali , Xu Maria C. , Privé Gilbert G. , He Housheng Hansen , Tiedemann Rodger E. , Chavez Elizabeth A. , Chong Lauren C. , Boyle Merrill , Scott David W. , Steidl Christian , Kridel Robert
Published: April 2023

Pathway analysis of RNA-seq results (lymphoid signatures).
Table S3 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Authors: Qu Yuan-Yuan , Zhang Hai-Liang , Guo Hongqian , Luo Hong , Zou Qing , Xing Nianzeng , Xia Shujie , Sun Zhongquan , Zhang Xuepei , He Chaohong , Cai Jinling , Zhang Xiao , Wang Quanren , Ye Ding-Wei
Published: April 2023

Immune-related adverse events
Supplementary Data from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Authors: Qu Yuan-Yuan , Zhang Hai-Liang , Guo Hongqian , Luo Hong , Zou Qing , Xing Nianzeng , Xia Shujie , Sun Zhongquan , Zhang Xuepei , He Chaohong , Cai Jinling , Zhang Xiao , Wang Quanren , Ye Ding-Wei
Published: April 2023

Supplementary Methods
Figure S1 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Authors: Qu Yuan-Yuan , Zhang Hai-Liang , Guo Hongqian , Luo Hong , Zou Qing , Xing Nianzeng , Xia Shujie , Sun Zhongquan , Zhang Xuepei , He Chaohong , Cai Jinling , Zhang Xiao , Wang Quanren , Ye Ding-Wei
Published: April 2023

Basket trial design
Supplementary Table S5 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Table S5 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure S4 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Authors: Kim Dae-Hwan , Sun Duanchen , Storck William K. , Welker Leng Katherine , Jenkins Chelsea , Coleman Daniel J. , Sampson David , Guan Xiangnan , Kumaraswamy Anbarasu , Rodansky Eva S. , Urrutia Joshua A. , Schwartzman Jacob A. , Zhang Chao , Beltran Himisha , Labrecque Mark P. , Morrissey Colm , Lucas Jared M. , Coleman Ilsa M. , Nelson Peter S. , Corey Eva , Handelman Samuel K. , Sexton Jonathan Z. , Aggarwal Rahul , Abida Wassim , Feng Felix Y. , Small Eric J. , Spratt Daniel E. , Bankhead Armand , Rao Arvind , Gesner Emily M. , Attwell Sarah , Lakhotia Sanjay , Campeau Eric , Yates Joel A. , Xia Zheng , Alumkal Joshi J.
Published: April 2023

Supplementary Figure S4 from BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
Supplementary Figure from Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma
Authors: Piper Miles , Van Court Benjamin , Mueller Adam , Watanabe Shuichi , Bickett Thomas , Bhatia Shilpa , Darragh Laurel B. , Mayeda Max , Nguyen Diemmy , Gadwa Jacob , Knitz Michael , Corbo Sophia , Morgan Rustain , Lee Jung-Jae , Dent Alexander , Goodman Karyn , Messersmith Wells , Schulick Richard , Del Chiaro Marco , Zhu Yuwen , Kedl Ross M. , Lenz Laurel , Karam Sana D.
Published: April 2023

Supplementary Figure from Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma
Supplementary Figure 1 from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Authors: Adams Sylvia , Othus Megan , Patel Sandip Pravin , Miller Kathy D. , Chugh Rashmi , Schuetze Scott M. , Chamberlin Mary D. , Haley Barbara J. , Storniolo Anna Maria V. , Reddy Mridula P. , Anderson Scott A. , Zimmerman Collin T. , O'Dea Anne P. , Mirshahidi Hamid R. , Ahnert Jordi Rodon , Brescia Frank J. , Hahn Olwen , Raymond Jane M. , Biggs David D. , Connolly Roisin M. , Sharon Elad , Korde Larissa A. , Gray Robert J. , Mayerson Edward , Plets Melissa , Blanke Charles D. , Chae Young Kwang , Kurzrock Razelle
Published: April 2023

Supplemental Figure 1: CONSORT Diagram
Table S2 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

Results of PLA, CD8 and PDL1 (MELscore) in all the samples
Supplementary Figure Legends from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

Supplementary Figure Legends
Figure S2 from A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma
Authors: Girault Isabelle , Adam Julien , Shen Shensi , Roy Séverine , Brard Caroline , Faouzi Sara , Routier Emilie , Lupu Jéremy , Warren Sarah , Sorg Kristina , Ong SuFey , Morel Pascale , Scoazec Jean-Yves , Vagner Stéphan , Robert Caroline
Published: April 2023

CD8+ cells immunohistochemistry. Infiltration of tumor areas (A) and peritumor areas (B) as assessed semi-quantitatively using a 0 to 3 scale.
Supplementary Figure from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Authors: Abdul Razak Albiruni R. , Bauer Sebastian , Suarez Cristina , Lin Chia-Chi , Quek Richard , Hütter-Krönke Marie Luise , Cubedo Ricardo , Ferretti Stephane , Guerreiro Nelson , Jullion Astrid , Orlando Elena J. , Clementi Giorgia , Sand Dejmek Janna , Halilovic Ensar , Fabre Claire , Blay Jean-Yves , Italiano Antoine
Published: April 2023

Supplementary Figure from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Supplementary Data from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Authors: Abdul Razak Albiruni R. , Bauer Sebastian , Suarez Cristina , Lin Chia-Chi , Quek Richard , Hütter-Krönke Marie Luise , Cubedo Ricardo , Ferretti Stephane , Guerreiro Nelson , Jullion Astrid , Orlando Elena J. , Clementi Giorgia , Sand Dejmek Janna , Halilovic Ensar , Fabre Claire , Blay Jean-Yves , Italiano Antoine
Published: April 2023

Supplementary Data from Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Authors: Chow Laura Q.M. , Barlesi Fabrice , Bertino Erin M. , van den Bent Martin J. , Wakelee Heather A. , Wen Patrick Y. , Chiu Chao-Hua , Orlov Sergey , Chiari Rita , Majem Margarita , McKeage Mark , Yu Chong-Jen , Garrido Pilar , Hurtado Felipe K. , Arratia Pilar Cazorla , Song Yuanbo , Branle Fabrice , Shi Michael , Kim Dong-Wan
Published: April 2023

Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Figure S9 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Bivariate analysis to fit all genes to sample ABSOLUTE purity score.
Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Authors: Chow Laura Q.M. , Barlesi Fabrice , Bertino Erin M. , van den Bent Martin J. , Wakelee Heather A. , Wen Patrick Y. , Chiu Chao-Hua , Orlov Sergey , Chiari Rita , Majem Margarita , McKeage Mark , Yu Chong-Jen , Garrido Pilar , Hurtado Felipe K. , Arratia Pilar Cazorla , Song Yuanbo , Branle Fabrice , Shi Michael , Kim Dong-Wan
Published: April 2023

Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
Figure S8 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Consequences of Mucin Alternative Splicing
Figure S7 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

Survival plots based on expression above (High Expression) or below (Low/No Expression) the non-zero median. Kaplan-Meier survival plots of the 3 mucin SVs significantly correlated with survival outcome but expressed at lower overall levels
Figure S4 from Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma
Authors: Thompson Christopher M. , Cannon Andrew , West Sean , Ghersi Dario , Atri Pranita , Bhatia Rakesh , Smith Lynette , Rachagani Satyayanarayana , Wichman Christopher , Kumar Sushil , Batra Surinder K.
Published: April 2023

PCA plots and survival
Supplementary Tables S1 and S2 from FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
Authors: Singh Sonia , Jaigirdar Adnan A. , Mulkey Flora , Cheng Joyce , Hamed Salaheldin S. , Li Yangbing , Liu Jiang , Zhao Hong , Goheer Anwar , Helms Whitney S. , Wang Xing , Agarwal Rajiv , Pragani Rajan , Korsah Kwadwo , Tang Shenghui , Leighton John , Rahman Atiqur , Beaver Julia A. , Pazdur Richard , Theoret Marc R. , Singh Harpreet
Published: April 2023

Supplementary Table 1 shows adverse reactions occurring at a frequency of 10% or higher in patients with SCLC who received lurbinectedin in Study B-005. Supplementary Table 2 shows select laboratory abnormalities as worsening from baseline and occurring at a rate of 20% or higher in patients with SCLC who received lurbinectedin in Study B-005.
Supplementary Data from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Authors: Atrafi Florence , Boix Oliver , Subbiah Vivek , Diamond Jennifer R. , Chawla Sant P. , Tolcher Anthony W. , LoRusso Patricia M. , Eder Joseph P. , Gutierrez Martin , Sankhala Kumar , Rajagopalan Prabhu , Genvresse Isabelle , Langer Simon , Mathijssen Ron H.J. , Verweij Jaap , Bruns Ingmar , Lolkema Martijn P.
Published: April 2023

Supplementary Data from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Supplementary Figures from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Authors: Jones Gregory D. , Caso Raul , Tan Kay See , Mastrogiacomo Brooke , Sanchez-Vega Francisco , Liu Yuan , Connolly James G. , Murciano-Goroff Yonina R. , Bott Matthew J. , Adusumilli Prasad S. , Molena Daniela , Rocco Gaetano , Rusch Valerie W. , Sihag Smita , Misale Sandra , Yaeger Rona , Drilon Alexander , Arbour Kathryn C. , Riely Gregory J. , Rosen Neal , Lito Piro , Zhang Haiying , Lyden David C. , Rudin Charles M. , Jones David R. , Li Bob T. , Isbell James M.
Published: April 2023

Supplementary Figures
Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Supplemental text and tables
Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Genomic alteration calls and clinical data
Supplementary Figure from Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Authors: Wei Shiyou , Yin Delong , Yu Shengnan , Lin Xiang , Savani Milan R. , Du Kuang , Ku Yin , Wu Di , Li Shasha , Liu Hao , Tian Meng , Chen Yaohui , Bowie Michelle , Hariharan Seethalakshmi , Waitkus Matthew , Keir Stephen T. , Sugarman Eric T. , Deek Rebecca A. , Labrie Marilyne , Khasraw Mustafa , Lu Yiling , Mills Gordon B. , Herlyn Meenhard , Wu Kongming , Liu Lunxu , Wei Zhi , Flaherty Keith T. , Abdullah Kalil , Zhang Gao , Ashley David M.
Published: April 2023

Supplementary Figure from Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Supplemental Figure 2 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Supplemental Figure S2. A. Comparison of treatment-related and -unrelated adverse events occurring in >10% of evaluable patients.
Supplemental Figure 1 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Stewart Caitlin M. , Michaud Laure , Whiting Karissa , Nakajima Reiko , Nichols Chelsea , De Frank Stephanie , Hamlin Paul A. , Matasar Matthew J. , Gerecitano John F. , Drullinsky Pamela , Hamilton Audrey , Straus David , Horwitz Steven M. , Kumar Anita , Moskowitz Craig H. , Moskowitz Alison , Zelenetz Andrew D. , Rademaker Jurgen , Salles Gilles , Seshan Venkatraman , Schöder Heiko , Younes Anas , Tsui Dana W.Y. , Batlevi Connie Lee
Published: April 2023

Supplemental Figure S1. Dosing of patients on study. A. MCL cohort. B. FL cohort. C. DLBCL cohort.
Supplementary Figure 4 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Authors: Zhao Shulin , Nicolle Rémy , Augustin Jérémy , Svrcek Magali , de Mestier Louis , Le Corre Delphine , Pietrasz Daniel , Caliez Olivier , Cros Jérôme , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

(A) Percentage of patients without observed relapse over 5 years in each model predicted prognosis group. (B-C) Prognostic values of the model predicted prognosis group and impact of adjuvant therapy evaluated by multivariate cox regression in all patients of both cohorts, except five patients without enough clinicopathological data (N=354). (B) Disease-free survival. (C) Overall survival.
Supplementary Figure 3 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Authors: Zhao Shulin , Nicolle Rémy , Augustin Jérémy , Svrcek Magali , de Mestier Louis , Le Corre Delphine , Pietrasz Daniel , Caliez Olivier , Cros Jérôme , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

Numbers of prognostic groups in each cohort.
Supplementary Figure 1 from Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components
Authors: Zhao Shulin , Nicolle Rémy , Augustin Jérémy , Svrcek Magali , de Mestier Louis , Le Corre Delphine , Pietrasz Daniel , Caliez Olivier , Cros Jérôme , Laurent-Puig Pierre , Bachet Jean-Baptiste
Published: April 2023

Comparison of AIC values of six PAC transcriptomic component levels, PAC whole-tumor subtypes by univariate cox regression and six PAC transcriptomic component levels by multivariate cox regression in all patients (N=359) for DFS and OS. (A) DFS. (B) OS.
Supplementary Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Authors: Cheng Zhao , Mirza Hasan , Ennis Darren P. , Smith Philip , Morrill Gavarró Lena , Sokota Chishimba , Giannone Gaia , Goranova Theodora , Bradley Thomas , Piskorz Anna , Lockley Michelle , Kaur Baljeet , Singh Naveena , Tookman Laura A. , Krell Jonathan , McDermott Jacqueline , Macintyre Geoffrey , Markowetz Florian , Brenton James D. , McNeish Iain A.
Published: April 2023

Supplementary Data from The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Percent Ivor J. , Babu Sunil , Cultrera Jennifer L. , Mehlhaff Bryan A. , Goodman Oscar B. , Morris David S. , Schnadig Ian D. , Albany Costantine , Shore Neal D. , Sieber Paul R. , Guba Susan C. , Zhang Wei , Wacheck Volker , Donoho Gregory P. , Szpurka Anna M. , Callies Sophie , Lin Boris Kin , Bendell Johanna C.
Published: April 2023

Supplementary Figure from Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S2 from Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials
Authors: Asleh Karama , Tu Dongsheng , Gao Dongxia , Bramwell Vivien , Levine Mark N. , Pritchard Kathleen I. , Shepherd Lois E. , Nielsen Torsten O.
Published: April 2023

Survival analysis showing the primary endpoint of disease-free survival for patients receiving tamoxifen (red lines) vs. placebo (black lines) in the MA.12 translational study cohort.
Supplementary Data from Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
Authors: Hanna Glenn J. , O'Neill Anne , Shin Kee-Young , Wong Kristine , Jo Vickie Y. , Quinn Charles T. , Cutler Jennifer M. , Flynn Michelle , Lizotte Patrick H. , Annino Donald J. , Goguen Laura A. , Kass Jason I. , Rettig Eleni M. , Sethi Rosh K.V. , Lorch Jochen H. , Schoenfeld Jonathan D. , Margalit Danielle N. , Tishler Roy B. , Everett Peter C. , Desai Anupam M. , Cavanaugh Megan E. , Paweletz Cloud P. , Egloff Ann Marie , Uppaluri Ravindra , Haddad Robert I.
Published: April 2023

Supplementary Data from Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
Supplementary Table 3 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Authors: Pizzamiglio Sara , Ciniselli Chiara Maura , Triulzi Tiziana , Gargiuli Chiara , De Cecco Loris , de Azambuja Evandro , Fumagalli Debora , Sotiriou Christos , Harbeck Nadia , Izquierdo Miguel , Nuciforo Paolo , Huober Jens , Cappelletti Vera , Cinieri Saverio , Piccart Martine , Daidone Maria Grazia , Pruneri Giancarlo , Colombo Mario Paolo , Tagliabue Elda , Verderio Paolo , Di Cosimo Serena
Published: April 2023

Table S3. Multivariate logistic model in the study cohort (n=226; 80 pCR and 64 events).